{
    "organizations": [],
    "uuid": "032f630c3bd1337ddd093ad98c22ba61323cf9e2",
    "author": "",
    "url": "https://www.reuters.com/article/brief-daiichi-sankyo-aligns-us-commercia/brief-daiichi-sankyo-aligns-u-s-commercial-operations-to-current-portfolio-upcoming-cancer-pipeline-idUSFWN1QI1I2",
    "ord_in_thread": 0,
    "title": "BRIEF-Daiichi Sankyo Aligns U.S. Commercial Operations To Current Portfolio, Upcoming Cancer Pipeline",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "February 28, 2018 / 8:02 PM / Updated 12 minutes ago BRIEF-Daiichi Sankyo Aligns U.S. Commercial Operations To Current Portfolio, Upcoming Cancer Pipeline Reuters Staff Feb 28 (Reuters) - Daiichi Sankyo : * DAIICHI SANKYO, INC. ALIGNS U.S. COMMERCIAL OPERATIONS TO CURRENT PORTFOLIO AND UPCOMING CANCER PIPELINE * DAIICHI SANKYO - ‍AS PART OF REORGANIZATION, CO WILL REDUCE HEADCOUNT BY ABOUT 280 EMPLOYEES FROM VARIOUS LOCATIONS IN THE U.S.​ Source text for Eikon: Further company coverage:",
    "published": "2018-02-28T22:02:00.000+02:00",
    "crawled": "2018-02-28T22:28:23.032+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "february",
        "pm",
        "updated",
        "minute",
        "ago",
        "sankyo",
        "aligns",
        "commercial",
        "operation",
        "current",
        "portfolio",
        "upcoming",
        "cancer",
        "pipeline",
        "reuters",
        "staff",
        "feb",
        "reuters",
        "daiichi",
        "sankyo",
        "daiichi",
        "sankyo",
        "aligns",
        "commercial",
        "operation",
        "current",
        "portfolio",
        "upcoming",
        "cancer",
        "pipeline",
        "daiichi",
        "sankyo",
        "part",
        "reorganization",
        "co",
        "reduce",
        "headcount",
        "employee",
        "various",
        "location",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}